Major cardiovascular events cause about 80% of the total mortality in diabetic patients. It has been shown that diabetic patients have hyperactive platelets. It may be expected that aspirin, through its antiplatelet action, could change the risk for vascular events in people with diabetes. However, some data suggest that aspirin may be less effective than expected in preventing cardiovascular events in patients with diabetes. In this paper, we review the aspirin use in diabetics with respect to cardiovascular endpoints.